To determine the role of intensive chemotherapy and allogeneic bone marrow transplantation (BMT) in treatment of refractory anemia with excess of blasts (RAEB) or RAEB-t (in transformation), the outcome of 37 consecutive children, 12 with RAEB and 25 with RAEB-t, diagnosed between 1985 and 1995 was analyzed. Fourteen patients received intensive chemotherapy according to the AML-BFM protocols 83, 87, or 93 (group 1). Seven patients were treated less intensively with the 6-week consolidation phase as induction (group 2). Allogeneic BMT was performed in 10 children of group 1 and 2 after, and in eight (group 3) without prior chemotherapy. Eight children received minimal or no chemotherapy (group 4). Of 21 children (groups 1 and 2) 17 (81%) achieved complete or partial remission after chemotherapy, 12 of them (10 of group 1) remained in remission, eight after BMT. Five-year survival in 29 children treated intensively (groups 1-3) was 46%, SE 12%. Two of the other eight children (group 4) remained alive, one after spontaneous remission. Outcome after BMT was related to the blast count in the bone marrow prior to BMT. None of 10 children (including two with minimal or no chemotherapy) with р12% blasts before BMT relapsed, in contrast to five of eight patients with a higher blast count (P log rank 0.02). We conclude that a substantial number of children with RAEB or RAEB-t can achieve remission with intensive AML-specific chemotherapy. In patients responding to intensive chemotherapy an increase in long-term survival after allogeneic BMT can be expected.
Introduction
Myelodysplastic syndromes (MDS) represent a group of clonal hematologic neoplastic disorders characterized by progressive cytopenia with or without leukemic transformation. While most patients with MDS are in the older age group, 1 MDS in children has been estimated to account for up to 9% of childhood leukemias. 2 We recently have published the experience of the European Working Group of MDS in Childhood (EWOG-MDS) on juvenile myelomonocytic leukemia (JMML), 3 the most common variant of MDS in childhood. In this paper we present a retrospective analysis of children with RAEB and RAEB-t registered at the study center of the German AML study from 1985 to 1995.
In young adult patients with RAEB and RAEB-t remission rates of more than 70% have been achieved with intensive AML-specific chemotherapy. While these remission rates are similar to those observed in de novo AML, durations of remissions were short. 4, 5 Currently, allogeneic bone marrow transplantation (BMT) is the treatment of choice for younger patients with a histocompatible sibling donor. Disease-free survival rates of 35-56% after a median follow-up of 20-73 months in young adults have been reported. [6] [7] [8] [9] [10] [11] [12] Transplant data of children are still relatively scarce. 13, 14 A review from the literature showed that 12 of 24 children were long-term survivors after allogeneic BMT. 15 However, the therapy given before BMT was very heterogenous and information is lacking on the response to treatment. As the value of AML-specific chemotherapy prior to BMT still remains unclear, we analyzed the outcome of 37 children with RAEB or RAEB-t with different treatment modalities including allogeneic BMT.
Patients and methods

Patients and diagnosis
Between March 1985 and December 1995, 37 children were diagnosed at the central laboratory for cytomorphology of the AML-BFM studies as suffering from primary RAEB or RAEB-t. As these patients were not included in the AML study, the registration might be incomplete. The morphological classification was based on the FAB criteria. 16 Patients with myelosarcoma (chloroma) who often present with a low blast count in the bone marrow were not included in the MDS group, because they were clinically and biologically distinct from MDS and were generally treated as de novo AML. 17 To determine the percentage of blast cells at least 400 nucleated bone marrow cells were examined. There were 14 patients classified as RAEB-t by the presence of Auer rods only. Results of the cytogenetic studies were available for 18 of the 37 patients. Nine children presented with a normal karyotype, four children had monosomy 7, two children had trisomy 8, and one child each had −8/−22, 20q-/2q-abnormality, and t(3;5)(q21q31).
Treatment
Therapy varied among the 37 children. Most of the children with more advanced MDS (RAEB-t) were treated with intensive AML treatment according to the AML-BFM strategy, while some received less intensive therapy, reflecting primarily the AML-study coordinators and physicians choice. Therapy of AML-BFM protocols -83/-87/-93 consisted of an 8-day ADE (cytosine-arabinoside = Ara-C/daunorubicin/etoposide) induction course, followed by a 6-week (in study AML-BFM-83 8-week) consolidation therapy and one or two blocks of intensification with high-dose Ara-C and etoposide or mitoxantrone (HAM). [18] [19] [20] Cranial irradiation and maintenance therapy were added in patients achieving CR. Complete remission (CR) was defined as a normocellular marrow with no evidence of residual disease and normal or near-normal blood count. As for partial remission (PR) no obligatory definition in MDS exists, we defined PR for this analysis as reduction of the blast cell count in the bone marrow Ͻ15%. Toxicity and realization of therapy in children receiving AML therapy were compared 
Statistical analysis
Survival was calculated from date of diagnosis to last followup or death from any cause. The Kaplan-Meier method 21 was used to estimate survival rates with comparisons based on the two-sided log rank test.
Results
Patient population and treatment groups
Of the 37 patients 12 children were classified as RAEB, 25 as RAEB-t ( Table 1) . The age at diagnosis ranged from 1.3 to 17.2 years (median 8.2). There were 17 girls and 20 boys. Fourteen children received intensive therapy according to the AML protocol with induction therapy (group 1), while in seven children less intensive AML therapy starting with the consolidation therapy and omitting the ADE induction was applied (group 2) ( Table 2 ). For groups 1 and 2 the median time between diagnosis and treatment was 0.5 months (range 0-11.6). Ten of the 21 children in groups 1 and 2 were transplanted, in median 5.5. months (range 4-19) after diagnosis. Eight children received an allogeneic BMT without previous intensive chemotherapy (group 3). The median time from diagnosis to BMT was 6.8 months (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Eight children received no or only minimal chemotherapy and no BMT (group 4). 
Overall results
Regarding the four treatment groups, estimated probabilities for survival after 5 years were: group 1, 74% (SE 17%); group 2, 21% (SE 18%); group 3, 36% (SE 20%); group 4, 17% (SE 15%). Of the 29 patients treated intensively (groups 1-3) 18 are alive, 12 after BMT (Table 2 ). Overall survival after 5 years was 46% (SE 12%) with a median follow-up of 1.9 years ( Figure 1) . Results for the eight children with no or only minimal therapy (group 4) were unfavorable with a median survival of 0.9 years (range 0.1-5.0).
Of the 18 patients transplanted, 13 received a graft from an HLA-identical matched family donor (MFD), one from a haploidentical parent, and four from an HLA-identical matched unrelated donor (MUD). The preparatory regimen included busulfan + cyclophosphamide ± VP-16 or melphalan (n = 10) or 12 Gy total body irradiation with cyclophosphamide ± VP-16 or thiotepa (n = 8).
Therapy results according to treatment groups Group 1 (Table 3) :
Fourteen children, all presenting with RAEB-t, were treated according to the AML-BFM-87 or -93 protocol with ADE induction. Eight of the 11 children treated within 1 month of diagnosis achieved CR. In three children therapy was initiated after progression to AML and one of them achieved CR. Overall, in 12 of the 14 patients there were three partial and nine complete responses. Of the seven children who achieved CR with chemotherapy and were not transplanted, three relapsed and four remained in CR at 0.5, 1.0, 4.0 and 9.7 years after diagnosis. Six patients were transplanted, two children in CR, three in PR and one in nonresponse. All six transplanted children are alive without evidence of disease.
Group 2 (Table 4):
Of the seven patients receiving AML-BFM therapy without ADE induction, two patients were treated after progression to AML. Four of the seven patients achieved remission, two of them relapsed and two remained in remission after BMT. Of the two children transplanted without achieving remission, one died from relapse and one due to complications of graft-versus-host disease (GVHD).
Regarding groups 1 and 2, two subsets of patients with dif- ferent prognoses could be identified: (1) 11 patients (one with RAEB, 10 with RAEB-t) treated within 0.5 months after diagnosis and a median blast count of 16% prior to chemotherapy; and (2) 10 children (five with RAEB-t, five after progression to AML) treated between 0.6 and 11.6 months after diagnosis with a median blast count of 30% before starting chemotherapy. The 5-year survival was significantly higher in the first subset of patients, compared to the second subset (83%, SE 15% vs 30%, SE 17%, P log rank 0.02). These data reflect that treatment was started without awaiting a further increase in blast count in about half of the patients, whereas in the other children an increase in blast count was waited for, thus delaying start of the treatment until progression to AML.
Group 3 (Table 5) : Eight patients were transplanted without or with only minimal AML specific pretreatment. Four of five patients given a BMT with a pretransplant blast count of 30% or more relapsed, while three patients with a blast count of 9, 10 and 25% remained in remission.
Group 4 (Table 6) :
Eight patients with RAEB received none or only minimal therapy without BMT. Two patients are still alive, one child after progression to AML, and one child presumably in CR. The latter child was 14 months old at diagnosis and displayed a monosomy 7 in hematopoietic cells. Hematopoiesis in this patient normalized spontaneously, monosomy 7 disappeared and the patient continues in remission for 5 years. 22 Results according to cytogenetic findings Nine of 18 children with cytogenetic findings were alive: five of nine with normal karyotype, two of four with monosomy 7, none of two with trisomy 8, and two of three with complex karyotypes.
Toxicity and therapy realization of AML therapy
There were no significant differences in the toxicity and in the realization of induction and consolidation of AML chemotherapy in the 14 children with RAEB-t (group 1) compared to those with de novo AML. Three of the 14 children (21%) with MDS required more than 4 weeks until the neutrophil count had recovered to Ͼ1.500/l compared to 45 of 108 children (42%) with AML treated in study AML-BFM-93. The median time from initiation of induction therapy to the beginning of the consolidation course was 27 days in both groups. The median time from initiation of therapy to the end of the first phase of consolidation therapy was 58 and 56 days, respectively. Febrile neutropenia occurred in most of the MDS (and AML) patients. Severe infections (sepsis and pneumonia) during induction therapy were reported in two of 14 (14%) of the intensively treated MDS patients, which is similar to that observed in children of study AML-BFM-93. In addition, severe infections were seen in two of 14 MDS patients during consolidation treatment and in three of seven patients receiving high-dose Ara-C.
Influence of remission and FAB status before BMT
The blast count in the bone marrow at the time of BMT had a major impact on relapse after BMT (Figure 2 ). None of the 10 patients transplanted with less than 12% (or Ͻ22%) blasts in the bone marrow (four in CR, five with RAEB) relapsed. In contrast, five of eight patients with у22% blasts (six with RAEB-t, two with progress to AML) suffered a relapse after BMT.
Discussion
Our analysis of the different treatment modalities in 37 children with RAEB or RAEB-t indicate that: (1) intensive AMLspecific treatment was well tolerated and could induce CR or at least PR in more than 70% of the patients; and (2) the blast count in the BM before BMT had a significant influence on survival after BMT.
During recent years intensive AML-specific chemotherapy has not generally been recommended in adults with RAEB or RAEB-t because CR rates were lower than in de novo AML 23, 24 and complications during chemotherapy-induced aplasia were high. Whereas in young adults response rates were higher 5 and Aul and Schneider 25 reported marked differences +, patient is alive.
Intensive AML-specific therapy for RAEB and RAEB-t in children U Creutzig et al 656 ChT, chemotherapy; Con, consolidation; HAM, HD-Ara-C/Mitox; FUO, fever of unknown origin; MFD, matched family donor; BMT, bone marrow transplantation; CR, complete remission; PR, partial remission; NR, nonresponse; inf, infection; +, patient is alive; GVHD, graftversus-host disease. in outcome between patients receiving or not receiving more intensive AML-specific chemotherapy.
To date, experiences in children are scarce due to the rarity of the diseases; and although chemotherapy is generally better tolerated than in adults, therapy according to the AML protocol was not always given because of the uncertain value.
In 14 children receiving this intensive AML treatment we failed to confirm a prolonged pancytopenic period or more severe infections compared to de novo AML patients. Remission rates of these patients were also comparable. However, these data have to be regarded with caution due to the low patient number.
Results were superior in those children treated soon after diagnosis compared to patients treated after several months, when a progress towards AML had mainly occurred. This confirms the findings in adults, where treatment results were extremely poor in patients with leukemia evolving from MDS. 24 Early treatment during the MDS phase is better tolerated and induces higher remission rates. However, spontaneous remission as seen in one of our patients may be possible.
Recently Niemeyer et al 3 reported a spontaneous recovery in two of 110 children with the MDS subtype JMML (one child with monosomy 7 and one with a normal karyotype). Both have been in remission for over 9 years. To date, these cases have been too rare to postpone treatment in the majority of patients.
Eight of our patients did not receive any or only minimal chemotherapy, either due to diagnostic difficulties or doubts about the feasibility of AML-specific chemotherapy, or because BMT was planned. BMT is currently regarded as the best treatment available in MDS; although, the role of prior chemotherapy has been controversially discussed. 26 Regarding BMT results, most investigators focus on the transplant characteristics: donor, conditioning regimen and GVHD prophylaxis. Children transplanted by an HLAidentical sibling had a significant better survival in comparison to patients using alternative donors, and no significant influence of the conditioning regimen has been observed; 27 however, the role of prior intensive chemotherapy was not stated.
Hasle et al 28 reported poor results in children with MDS after intensive chemotherapy in contrast to allogeneic BMT without prior chemotherapy. However, all children without chemotherapy prior to BMT had less than 20% blasts and patient numbers were low. Furthermore, these 20 MDS patients included two RA patients and eight JMML patients. We excluded these subtypes from our analyses because intensive chemotherapy prior to BMT seemed not to be necessary in RA and was unlikely to influence outcome in JMML. 3 Recently, Demuynck et al 29 demonstrated in 24 adults (median age 30 years) with MDS that the status of the underlying disease at the time of conditioning was the major factor determining long-term survival. The disease-free survival of patients with RAEB and RAEB-t transplanted in CR was over 50% compared to zero in patients with persistent disease. In this study the transplant-related mortality was 50%, mainly due to severe acute GVHD because of using alternative donors.
Our results indicate remarkable differences in disease-free survival after BMT in relation to the marrow blast count before BMT, confirming common oncologic knowledge, that results are better with a lower leukemic cell burden.
According to our experience in children, long-term results were superior after achieving remission or partial remission with intensive chemotherapy prior to BMT. At least in children, AML therapy was not too toxic and resulted in relatively high remission rates. All six children transplanted after AML chemotherapy including ADE induction remained in CR, whereas half of the patients with less intensive or no AML therapy prior to BMT died. Results of MUD BMT in four children did not show any disadvantage in our study.
So far, the number of reported MDS patients with MUD is low and results are generally less satisfactory, mainly due to the high mortality from the transplant procedure. 27, 30, 31 We recommend treatment of patients with RAEB or RAEB-t with more than 15% blasts in the bone marrow with AMLspecific therapy shortly after diagnosis and before BMT. This was a consensus of the European Working Group on Myelodysplastic Syndromes (EWOG-MDS). The cutoff-point of 15% blasts is arbitrary because data were insufficient for this parameter. Patients with an HLA-identical family donor and a lower blast count may be transplanted without AML treatment. If no HLA-identical sibling is available, intensive AML-specific chemotherapy seems to be an option to improve survival without BMT; MUD may also be considered. Both therapy options require further evaluation with higher childhood patient numbers.
